


LISTING OF CLAIMS:

Claims 1-22 Canceled.

23. (Previously Amended) A compound of the formula



(I)

wherein

R represents phenyl, naphthyl, thienyl, pyridinyl or pyridazinyl ring, said phenyl ring being optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen a heterocyclcyl, lower alkylcarbonyl, formyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and said pyridinyl or pyridazinyl being optionally substituted in one or two positions with lower alkoxy, amino, or halogen;

X is -O- or >C=Y, wherein Y is oxygen;










R¹ represents hydrogen, hydroxy-lower alkyl, cyano-lower alkyl, or lower alkyl-carbonyl; and













R², R³, R⁴, R⁵ and R⁶ is hydrogen;















or a pharmaceutically acceptable salt thereof.








24. (Previously Amended) The compound of claim 23 where X is $>C=Y$, wherein Y is oxygen, or it's pharmaceutically acceptable salts.

25. (Previously Amended) The compound of claim 24, which compounds are selected from the group consisting of the compounds 1, 5, 6, 11, 14, 15, 16, 19, 23, 29, 35, 41, 42, 44, 45, 46, 47, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 65, 66, 67, 68, 69, 70, 72, 74, 76, 77, 78 and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
1		H
5		(CO)CH ₃
6		CH ₂ CH ₂ CN
11		CH ₂ CH ₂ CH ₂ OH
14		H
15		H
16		H
19		H
23		H

29		H
35		H
41		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
52		CH ₂ CH ₂ CH ₂ OH
53		H


54		$\text{CH}_2\text{CH}_2\text{CN}$
55		H
56		$\text{CH}_2\text{CH}_2\text{CN}$
57		$\text{CH}_2\text{CH}_2\text{CN}$
58		$\text{CH}_2\text{CH}_2\text{CN}$
59		H
61		$\text{CH}_2\text{CH}_2\text{CN}$
62		H
64		H
65		H
66		H
67		H
68		H
69		$\text{CH}_2\text{CH}_2\text{CN}$














70		H
72		H
74		H
76		H
77		H
78		H
79		CH ₂ CH ₂ CN






or their pharmaceutically acceptable salts.

26. (Previously Submitted) The compound of claim 24 wherein R¹ represents hydrogen or cyano-lower alkyl.

27. (Previously Amended) The compound of claim 26 wherein the compounds are selected from the group consisting of the compounds 6, 15, 29, 42, 44, 45, 46, 47, 48, 50, 54, 56, 58, 61, 64, 65, 70, 78 and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
6		CH ₂ CH ₂ CN

15		H
29		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
54		CH ₂ CH ₂ CN
56		CH ₂ CH ₂ CN
58		CH ₂ CH ₂ CN
61		CH ₂ CH ₂ CN


64		H
65		H
70		H
78		H
79		CH ₂ CH ₂ CN

or their pharmaceutically acceptable salts.

28. (Previously Submitted) The compound of claim 24, wherein R is optionally substituted phenyl.

29. (Previously Submitted) The compound of Claim 28 wherein said compound is 4-[1-(4-aminophenacyl)-1H-benzimidazol-2-yl]-furazan-3-yl-N-(2-cyanoethyl)-amine or pharmaceutically acceptable salts thereof.

30. (Previously Submitted) The compound of claim 26 where the compound has the formula



(I)

wherein

R is pyridinyl optionally substituted in one or two positions by lower alkoxy, amino, or halogen;

X is -C=O; O is oxygen ;

R¹ is cyano-lower alkyl or hydrogen and;

R², R³, R⁴, R⁵, R⁶ is hydrogen;

or a pharmaceutically acceptable salt thereof.


31. (Previously Submitted) The compound of Claim 30 wherein R¹ is cyano-lower alkyl.

32. (Currently Amended) The compound of Claim 31 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonyl)methyl]-1H-benzimidazol-2-yl]-furazan-2-yl]-N-(2-cyanoethyl)-amine or its pharmaceutical acceptable salts.

33. (Previously Submitted) The compound of Claim 30 wherein R¹ is hydrogen.







34. (Currently Amended) The compound of Claim 33 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonyl)methyl]-1H-benzimidazol-2-yl]-furazan-3-ylamine; or pharmaceutical acceptable salts thereof.

35. (Previously Amended) The compound of claim 28 where said compound has the formula






which compound is selected from the group consisting of the compounds 7, 10, 88, 89, 92, 93, 94, 95, 96, 97, 101 and 103, which compounds are set forth according to the following table:


Compound	R	R ¹
7		H
10		CH ₂ CH ₂ CN
88		H
89		H
92		H
93		CH ₂ CH ₂ CN

94		CH ₂ CH ₂ CN
95		CH ₂ CH ₂ CN
96		H
97		H
101		H
103		H

or pharmaceutically acceptable salts thereof.


36. (Previously Amended) The compound of claim 35, which compound is selected from the group consisting of the compounds 89, 92, 94 and 101, which compound are set forth according to the following table:

Compound	R	R'
89		H
92		H
94		CH ₂ CH ₂ CN

101		H
-----	---	---

or their pharmaceutically acceptable salts.

37. (Previously Amended) A compound of the formula (I)



wherein

R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen a heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;



X is -C= Y and Y is nitrogen substituted by an alkoxy;

R¹ represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl;

R², R³ and R⁶ represent hydrogen;


R⁴ and R⁵, independently of each other, represent hydrogen, lower alkyl or lower alkoxy;
or R⁴ and R⁵ together represent methylenedioxy; or
pharmaceutically acceptable salts thereof.

38. (Previously Amended) The compound of claim 37, which compound is selected from the group consisting of the compounds 18 and 22, which compounds are set forth according to the following table:



Compound	R	R ¹
18		H
22		H

or their pharmaceutically acceptable salts.

39. (Currently Amended) A compound selected from the group consisting of the Compounds 9 and 13, which compounds **are as represented by the following formula and** are set forth according to the following table:



wherein Y is oxygen

Compound	R	R ¹
9		$\text{CH}_2\text{CH}_2(\text{CO})\text{OCH}_3$
13		$\text{CH}_2\text{CH}_2(\text{CO})\text{OH}$

or their pharmaceutically acceptable salts.